Managing Gynecologic Screening

Documents to Request

• Prior Pap smear results with Bethesda classification
• HPV testing results (genotyping: HPV 16/18 vs. other high-risk types)
• Colposcopy reports and biopsy pathology
• Prior LEEP/cone operative and pathology reports
• HIV test results
• Immunization records (HPV vaccine series)

Step 1: Apply Age-Based Screening Intervals

Per USPSTF/ACOG/ACS/ASCCP recommendations:

Special populations:

• HIV-positive: Begin screening at age 21, cytology annually; co-testing every 3 years if age ≥ 30 with normal results × 3
• Immunosuppressed (non-HIV): Screen per HIV guidelines
• In utero DES exposure: Annual cytology starting at age of diagnosis

Step 2: Interpret Results Using the Bethesda System

Cytology Categories (Bethesda 2014)

HPV Results

• HPV negative — low risk, return to routine screening
• HPV positive (other high-risk, non-16/18) — risk depends on cytology
• HPV 16 positive — highest risk; colposcopy regardless of cytology
• HPV 18 positive — high risk; colposcopy regardless of cytology

Step 3: Apply the 2019 ASCCP Risk-Based Framework

Management is based on the estimated CIN 3+ risk using current and prior test results:

Key clinical action thresholds:

• ASC-US / HPV negative: Return in 3 years (low risk)
• ASC-US / HPV positive (non-16/18): Return in 1 year
• ASC-US / HPV 16 or 18 positive: Colposcopy
• LSIL / HPV negative (ages 25+): Return in 1 year
• LSIL / HPV positive: Colposcopy
• HSIL (any HPV result): Colposcopy; expedited treatment (LEEP) acceptable if not pregnant
• AGC: Colposcopy + ECC + endometrial biopsy (if age ≥ 35 or risk factors for endometrial cancer)

Step 4: Colposcopy Documentation Requirements

When colposcopy is performed, document:

1. Indication — cytology result, HPV status, ASCCP risk estimate
2. Adequacy — visualization of entire squamocolumnar junction (SCJ) — adequate vs. inadequate
3. Findings — acetowhite epithelium, punctation, mosaicism, atypical vessels, lesion size and location (clock positions)
4. Biopsy location(s) — number and clock positions of biopsies taken
5. Endocervical curettage (ECC) — performed or not, indication
6. Impression — low-grade vs. high-grade colposcopic impression
7. Pathology results — CIN 1, CIN 2, CIN 3, AIS, invasive carcinoma
8. Management plan — surveillance vs. excision based on pathology and ASCCP guidelines

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the screening interval appropriate for the patient's age and risk profile?
2. Are all test results documented with Bethesda terminology for cytology and specific HPV genotype data?
3. Does the management plan match the ASCCP risk-based recommendation for the test result combination?
4. Is the colposcopy referral documented when indicated, or is the surveillance plan clearly stated?
5. Are special populations flagged — HIV, immunosuppressed, post-treatment, DES exposure?

Quality Audit

• Patient age documented and screening interval matches age-based recommendation
• Cytology result documented using Bethesda System terminology
• HPV result documented with genotype specificity (16, 18, other high-risk, negative)
• ASCCP risk estimate or risk category is stated
• Colposcopy referral documented when CIN 3+ risk ≥ 4%
• Colposcopy adequacy (SCJ visualization) documented when performed
• Biopsy results documented with CIN grade
• ECC performed and results documented for AGC or unsatisfactory colposcopy
• Prior abnormal results are referenced when estimating current risk
• Treatment plan (surveillance vs. excision) is stated with next follow-up date
• HIV and immunosuppression screening protocols applied when applicable
• Post-treatment surveillance documented (at 6 months, 12 months, then annually × 3 years, then every 3 years × 25 years)
• HPV vaccination status documented and vaccine offered if eligible (up to age 45)

Guidelines

1. Use Bethesda terminology exclusively — never write "Class II" or "mild dysplasia" in place of the standardized Bethesda terms.
2. Always pair cytology with HPV result — isolated cytology interpretation without HPV context leads to incorrect risk estimation.
3. Do not over-screen — annual Pap smears are not recommended for average-risk patients over age 30 with negative co-testing; the interval is 5 years.
4. Age 21–24 is a special group — LSIL and ASC-US in this age group are managed conservatively due to high regression rates. Do NOT perform HPV co-testing.
5. AGC triggers a broader workup — always include ECC and consider endometrial biopsy, especially in patients ≥ 35 or with abnormal bleeding.
6. Post-treatment surveillance is 25 years — patients with treated CIN 2+ remain at elevated risk for at least 25 years and must not return to standard population-based screening intervals.
7. Document the "adequate negative prior" determination when discontinuing screening at age 65 — list the specific tests and dates that meet exit criteria.